HepC/Cancer Nontoxic Med Hemopurifier ADAPT System Filters outExomes
EMD)JAMES A. JOYCE is the Founder, Chairman and Chief Executive Officer of Aethlon Medical, Inc. He has originated numerous collaborative relationships with government and nongovernment research organizations, has authored supporting publications and reports, and raised capital resources to support the mission of Aethlon Medical. He has represented the company on CNN, NBC, ABC and other media outlets, and has testified in front of Congress. From February 1993 until founding Aethlon Medical, Mr. Joyce was CEO of James Joyce & Associates. Previously, he was Founder and CEO of Mission Labs, Inc., was a Principal at London Zurich Securities, Inc., and was a member of the Denver Broncos Football Club of the National Football League. Mr. Joyce is a graduate of The University of Maryland.C O M P A N Y I N T E R V I E WR E P R I N T E D F R O M A U G U S T 2 0 , 2 0 1 2SECTOR — HEALTH SERVICESTWST:Would you begin with a brief historical sketch of the company and a picture of its operations at the present time?Mr. Joyce: The genesis of Aethlon Medical was based on the vision that we could create a medical device that would selectively eliminate disease-causing factors from the entire circulatory system, and do so without drug toxicity. I’m proud to say that just over a decade later, we’ve transformed that vision into a reality. We’re now creating medicaldevice-based therapies to address unmet medical needs in cancer, hepatitis C and other major market disease conditions.We’ve also received a contract from the U.S. government to create a device that will reduce the incidence of sepsis, which is often the cause of death in wounded war fighters.TWST: Please tell us briefly about the science behind these therapies. It sounds as if Aethlon Medical developed numerous products from one platform.Mr. Joyce: In the beginning, the idea of selectively eliminating hepatitis-C- or cancer-promoting factors from the entire circulatory system was theoretical, at best. However, from a science perspective, we believed that intersecting the capabilities of affinity drug agents with advanced plasma filtration membranes would result in a platform technology that would support our therapeutic objectives. We call this platform the Aethlon ADAPT System, which is an acronym for adaptive dialysis-like affinity platform technology. The ADAPT system allows us to immobilize single or multiple affinity agents within a medical device designed to subtract deleterious targets from circulation versus adding toxic drug agents into circulation.Our lead product from the ADAPT system is the Aethlon Hemopurifier. The Hemopurifier has demonstrated broad spectrum capabilities against infectious viral pathogens that include bioterror threats, pandemic threats and HIV. In human studies, our primary focus to date has been hepatitis C. We have approximately 100 hepatitis C treatments under our belt, and we’ve demonstrated that the Hemopurifier can rapidly reduce viral load. We are now preparing to initiate commercialization of the Hemopurifier overseas and anticipate the initiation of human clinical programs in the United States early next year.We’ve also discovered that our Hemopurifier is able to capture cancer-secreted exosomes, which are extremely immunosuppressive in cancer patients. Exosomes have also been reported to promote angiogenesis, which is the ability for tumors to create their own blood supply for survival, and in the latest issue of the journal Nature, exosomes were reported to seed the spread of metastasis in cancer patients. That said, exosomes represent a critically important target that can be addressed by our Hemopurifier, yet remain beyond the reach of traditional drug therapies.TWST: So potentially, there’s a gigantic market for these therapies?Mr. Joyce: Yes, the opportunity is enormous for a device that offers to improve infectious disease and cancer treatment regimens without adding drug toxicity or interaction risks. In just the hepatitis C space alone, immense valuations are being put on promising new therapies. As an example, Gilead recently paid $11 billion for Pharmasset, based on a promising clinical-stage drug.
EMD)JAMES A. JOYCE is the Founder, Chairman and Chief Executive Officer of Aethlon Medical, Inc. He has originated numerous collaborative relationships with government and nongovernment research organizations, has authored supporting publications and reports, and raised capital resources to support the mission of Aethlon Medical. He has represented the company on CNN, NBC, ABC and other media outlets, and has testified in front of Congress. From February 1993 until founding Aethlon Medical, Mr. Joyce was CEO of James Joyce & Associates. Previously, he was Founder and CEO of Mission Labs, Inc., was a Principal at London Zurich Securities, Inc., and was a member of the Denver Broncos Football Club of the National Football League. Mr. Joyce is a graduate of The University of Maryland.C O M P A N Y I N T E R V I E WR E P R I N T E D F R O M A U G U S T 2 0 , 2 0 1 2SECTOR — HEALTH SERVICESTWST:Would you begin with a brief historical sketch of the company and a picture of its operations at the present time?Mr. Joyce: The genesis of Aethlon Medical was based on the vision that we could create a medical device that would selectively eliminate disease-causing factors from the entire circulatory system, and do so without drug toxicity. I’m proud to say that just over a decade later, we’ve transformed that vision into a reality. We’re now creating medicaldevice-based therapies to address unmet medical needs in cancer, hepatitis C and other major market disease conditions.We’ve also received a contract from the U.S. government to create a device that will reduce the incidence of sepsis, which is often the cause of death in wounded war fighters.TWST: Please tell us briefly about the science behind these therapies. It sounds as if Aethlon Medical developed numerous products from one platform.Mr. Joyce: In the beginning, the idea of selectively eliminating hepatitis-C- or cancer-promoting factors from the entire circulatory system was theoretical, at best. However, from a science perspective, we believed that intersecting the capabilities of affinity drug agents with advanced plasma filtration membranes would result in a platform technology that would support our therapeutic objectives. We call this platform the Aethlon ADAPT System, which is an acronym for adaptive dialysis-like affinity platform technology. The ADAPT system allows us to immobilize single or multiple affinity agents within a medical device designed to subtract deleterious targets from circulation versus adding toxic drug agents into circulation.Our lead product from the ADAPT system is the Aethlon Hemopurifier. The Hemopurifier has demonstrated broad spectrum capabilities against infectious viral pathogens that include bioterror threats, pandemic threats and HIV. In human studies, our primary focus to date has been hepatitis C. We have approximately 100 hepatitis C treatments under our belt, and we’ve demonstrated that the Hemopurifier can rapidly reduce viral load. We are now preparing to initiate commercialization of the Hemopurifier overseas and anticipate the initiation of human clinical programs in the United States early next year.We’ve also discovered that our Hemopurifier is able to capture cancer-secreted exosomes, which are extremely immunosuppressive in cancer patients. Exosomes have also been reported to promote angiogenesis, which is the ability for tumors to create their own blood supply for survival, and in the latest issue of the journal Nature, exosomes were reported to seed the spread of metastasis in cancer patients. That said, exosomes represent a critically important target that can be addressed by our Hemopurifier, yet remain beyond the reach of traditional drug therapies.TWST: So potentially, there’s a gigantic market for these therapies?Mr. Joyce: Yes, the opportunity is enormous for a device that offers to improve infectious disease and cancer treatment regimens without adding drug toxicity or interaction risks. In just the hepatitis C space alone, immense valuations are being put on promising new therapies. As an example, Gilead recently paid $11 billion for Pharmasset, based on a promising clinical-stage drug.
EMD)JAMES A. JOYCE is the Founder, Chairman and Chief Executive Officer of Aethlon Medical, Inc. He has originated numerous collaborative relationships with government and nongovernment research organizations, has authored supporting publications and reports, and raised capital resources to support the mission of Aethlon Medical. He has represented the company on CNN, NBC, ABC and other media outlets, and has testified in front of Congress. From February 1993 until founding Aethlon Medical, Mr. Joyce was CEO of James Joyce & Associates. Previously, he was Founder and CEO of Mission Labs, Inc., was a Principal at London Zurich Securities, Inc., and was a member of the Denver Broncos Football Club of the National Football League. Mr. Joyce is a graduate of The University of Maryland.C O M P A N Y I N T E R V I E WR E P R I N T E D F R O M A U G U S T 2 0 , 2 0 1 2SECTOR — HEALTH SERVICESTWST:Would you begin with a brief historical sketch of the company and a picture of its operations at the present time?Mr. Joyce: The genesis of Aethlon Medical was based on the vision that we could create a medical device that would selectively eliminate disease-causing factors from the entire circulatory system, and do so without drug toxicity. I’m proud to say that just over a decade later, we’ve transformed that vision into a reality. We’re now creating medicaldevice-based therapies to address unmet medical needs in cancer, hepatitis C and other major market disease conditions.We’ve also received a contract from the U.S. government to create a device that will reduce the incidence of sepsis, which is often the cause of death in wounded war fighters.TWST: Please tell us briefly about the science behind these therapies. It sounds as if Aethlon Medical developed numerous products from one platform.Mr. Joyce: In the beginning, the idea of selectively eliminating hepatitis-C- or cancer-promoting factors from the entire circulatory system was theoretical, at best. However, from a science perspective, we believed that intersecting the capabilities of affinity drug agents with advanced plasma filtration membranes would result in a platform technology that would support our therapeutic objectives. We call this platform the Aethlon ADAPT System, which is an acronym for adaptive dialysis-like affinity platform technology. The ADAPT system allows us to immobilize single or multiple affinity agents within a medical device designed to subtract deleterious targets from circulation versus adding toxic drug agents into circulation.Our lead product from the ADAPT system is the Aethlon Hemopurifier. The Hemopurifier has demonstrated broad spectrum capabilities against infectious viral pathogens that include bioterror threats, pandemic threats and HIV. In human studies, our primary focus to date has been hepatitis C. We have approximately 100 hepatitis C treatments under our belt, and we’ve demonstrated that the Hemopurifier can rapidly reduce viral load. We are now preparing to initiate commercialization of the Hemopurifier overseas and anticipate the initiation of human clinical programs in the United States early next year.We’ve also discovered that our Hemopurifier is able to capture cancer-secreted exosomes, which are extremely immunosuppressive in cancer patients. Exosomes have also been reported to promote angiogenesis, which is the ability for tumors to create their own blood supply for survival, and in the latest issue of the journal Nature, exosomes were reported to seed the spread of metastasis in cancer patients. That said, exosomes represent a critically important target that can be addressed by our Hemopurifier, yet remain beyond the reach of traditional drug therapies.TWST: So potentially, there’s a gigantic market for these therapies?Mr. Joyce: Yes, the opportunity is enormous for a device that offers to improve infectious disease and cancer treatment regimens without adding drug toxicity or interaction risks. In just the hepatitis C space alone, immense valuations are being put on promising new therapies. As an example, Gilead recently paid $11 billion for Pharmasset, based on a promising clinical-stage drug.
Replies